Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000011.xml
Dtsch Med Wochenschr 2011; 136(36): 1788
DOI: 10.1055/s-0031-1286102
DOI: 10.1055/s-0031-1286102
Pro & Contra | Commentary
Gastroenterologie
© Georg Thieme Verlag KG Stuttgart · New York
Biologika als Erstlinientherapie bei chronisch entzündlichen Darmerkrankungen – pro
Biologicals first-line in chronic inflammatory bowel disease? YesFurther Information
Publication History
Publication Date:
31 August 2011 (online)
Schlüsselwörter
chronisch entzündliche Darmerkrankungen - Biologika - Erstlinientherapie
Keywords
chronic inflammatory bowel disease - biologicals - first-line therapy
Literatur
- 1 Faubion Jr W A, Loftus Jr E V, Harmsen W S. et al . The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology. 2001; 121 255-260
- 2 Herrlinger K, Stange E F. Treatment of Crohn’s disease: step-up or top-down?. Dtsch Med Wochenschr. 2010; 135 1694-1698
- 3 Feagan B G, Panaccione R, Sandborn W J. et al . Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn’s disease: results from the CHARM study. Gastroenterology. 2008; 135 1493-1499
- 4 de Pineton Chambrun G, Peyrin-Biroulet L, Lémann M, Colombel J F. Clinical implications of mucosal healing for the management of IBD. Nat Rev Gastroenterol Hepatol. 2010; 7 15-29
- 5 Van Assche G, Vermeire S, Rutgeerts P. The potential for disease modification in Crohn's disease. Nat Rev Gastroenterol Hepatol. 2010; 7 79-85
Prof. Dr. Andreas Stallmach
Abteilung für Gastroenterologie, Hepatologie
und Infektiologie
Klinik für Innere Medizin II
Friedrich-Schiller-Universität
Erlanger Allee 101
07740 Jena
Email: Andreas.Stallmach@med.uni-jena.de